Kenyan IV Solutions Manufacturer
Sterile Normal Saline and Dextrose IV solutions manufactured in Kenya for Kenyan healthcare facilities.
Pioneering locally manufactured sterile IV solutions.
Our Mission
To revolutionize healthcare in East Africa by providing accessible, sterile, and locally manufactured IV solutions services that meet the highest quality standards, thereby enhancing patient safety and improving patient life.
Our Story
Transforming East African Healthcare
Bryant, Mitchell & Omondi (BMO) was founded with a clear vision: to revolutionize healthcare delivery in East Africa by providing accessible, high-quality sterile intravenous solutions manufactured locally to meet local needs.
For decades, East African healthcare facilities have relied heavily on imported IV solutions, creating vulnerabilities in the supply chain, inflated costs, and dependencies on foreign manufacturers. BMO was established to address this critical gap by bringing world-class pharmaceutical manufacturing to Nairobi, Kenya.
Our state-of-the-art facility combines advanced sterilization technology with rigorous quality control processes, producing Normal Saline and Dextrose IV solutions that meet international pharmaceutical standards, while remaining affordable and consistently available to healthcare providers across the region, ultimately enhancing the East African community.
Our Vision
Our goal is to become the leading manufacturer and distributor of sterile IV solutions in East Africa, recognized for quality excellence and innovation, while enhancing health solutions that improve outcomes of healthcare facilities across the region.
Co-founder
George Mitchell, MHA - Managing Partner
George brings extensive healthcare administration and policy expertise to BMO, with a distinguished career spanning federal government service with the Administration of Children and Families and the Centers of Disease Control and Prevention. At the CDC, George represented the organization on Capitol Hill, working closely with lawmakers and their staff to protect the public health of millions through innovative health solutions.
Trained as a hospital administrator at the Graduate School of Public Health at the University of Pittsburgh, he has managed multimillion-dollar hospital budgets and oversaw personnel of approximately 200, while developing a deep operational knowledge of pharmaceutical procurement and healthcare supply chains services.
His experience as Policy Director at the Administration for Children and Families (ACF) within the Department of Healthand Human Services provided invaluable insights into healthcare policy, regulatory compliance, and program development. With a commitment to public health, George co-founded Chronic Care Innovators (CCI), demonstrating his entrepreneurial vision and dedication to healthcare innovation and enhancing patient outcomes.
George's strategic leadership focuses on building sustainable healthcare infrastructure, establishing international pharmaceutical partnerships, and positioning BMO as East Africa's premier IV solution manufacturer.
Our Values
Quality Excellence
We maintain an unwavering commitment to pharmaceutical quality standards, ensuring every product meets rigorous safety and efficacy requirements, contributing to effective health solutions.
Patient Safety
Patient wellbeing drives every decision we make, from raw material sourcing to final product distribution."reinforcing our dedication to improved outcomes.
Local Empowerment
By manufacturing locally, we create jobs, support regional economies, and build sustainable healthcare infrastructure to enhance health solutions in our communities.
Innovation
We continuously invest in research and development to create customized health solutions that address the unique healthcare challenges of East Africa.
Reliability
Healthcare providers depend on us for a consistent supply of sterile IV solutions, and we honor that trust with operational excellence and responsive service.
Integrity
We operate with transparency, ethical business practices, and accountability to our customers, partners, and communities, fostering trust in our sterile IV solutions.
Co-founder
Dr. Maxwell Omondi, MD - Chief Medical Officer
Dr. Omondi brings essential clinical expertise and a deep understanding of East African healthcare needs to BMO. As a practicing physician in Kenya, he has firsthand experience with the challenges healthcare providers face in accessing reliable, affordable IV solutions.
His medical expertise guides BMO's product development, ensuring our formulations address the specific clinical requirements of East African patient populations while enhancing wellness services. Dr. Omondi oversees quality assurance protocols, clinical consultation services, and relationships with healthcare providers across the region.
His vision of locally manufactured, internationally certified pharmaceutical products positions BMO to serve as a trusted healthcare partner for hospitals, clinics, and medical facilities throughout East Africa.
80% - 90% of Hospital Visits Require IV
About the IV Fluids
We are committed to shifting the paradigm of healthcare delivery in Nairobi, throughout Kenya, and regions of East Africa.
About the IV Fluids
State-of-the-Art Manufacturing in Nairobi
BMO's manufacturing facility in Nairobi represents a significant investment in East Africa's pharmaceutical infrastructure, contributing to innovative health solutions in the region. Our facility features:
Advanced Sterilization Technology
- Validated autoclaving processes
- Aseptic filling systems with 99.5% accuracy
- Time-pressure control filling technology
- Continuous environmental monitoring
Quality Control Laboratory
- In-house sterility testing
- Endotoxin analysis
- Chemical composition verification
- Container integrity testing
- Stability studies
Cleanroom Environments
- ISO Class 7 manufacturing zones
- Positive pressure filtration systems
- HEPA filtration throughout
- Regular environmental monitoring
- Strict personnel protocols
Compliance & Certifications
- WHO Good Manufacturing Practices (GMP)
- Kenya Pharmacy and Poisons Board approval
- ISO 9001:2015 Quality Management Systems
- Regular third-party audits
- Full batch documentation and traceability
Local Manufacturing, Regional Impact
Supporting Local Economies
BMO prioritizes local sourcing for raw materials and services, creating employment opportunities and supporting Kenya's industrial development.
Reducing Import Dependency
By manufacturing locally, we help East African healthcare systems reduce vulnerability to international supply chain disruptions.
Competitive Pricing
Local production eliminates import duties, shipping costs, and intermediary markups, allowing us to offer competitive pricing without compromising quality.
Reliable Supply
Our Nairobi location ensures consistent availability and rapid response to healthcare facility needs across Kenya and East Africa.
Healthcare Infrastructure Development
We actively partner with healthcare providers, training institutions, and government agencies to strengthen regional medical capabilities.
Our Commitment
Quality & Safety
Partnership and Collaboration
Partnership and Collaboration
To revolutionize healthcare in East Africa by providing accessible, sterile, and locally manufactured IV solutions services that meet the highest quality standards, thereby enhancing patient safety and improving patient life.
Partnership and Collaboration
Partnership and Collaboration
Partnership and Collaboration
Transforming East African Healthcare
Bryant, Mitchell & Omondi (BMO) was founded with a clear vision: to revolutionize healthcare delivery in East Africa by providing accessible, high-quality sterile intravenous solutions manufactured locally to meet local needs and enhance health solutions in the region.
For decades, East African healt
Transforming East African Healthcare
Bryant, Mitchell & Omondi (BMO) was founded with a clear vision: to revolutionize healthcare delivery in East Africa by providing accessible, high-quality sterile intravenous solutions manufactured locally to meet local needs and enhance health solutions in the region.
For decades, East African healthcare facilities have relied heavily on imported IV solutions, creating vulnerabilities in the supply chain, inflated costs, and dependencies on foreign manufacturers. BMO was established to address this critical gap by bringing world-class pharmaceutical manufacturing to Nairobi, Kenya.
Our state-of-the-art facility combines advanced sterilization technology with rigorous quality control processes, producing Normal Saline and Dextrose IV solutions that meet international pharmaceutical standards. These services remain affordable and consistently available to healthcare providers across the region, ultimately enhancing community health.
Community Engagement
Partnership and Collaboration
Community Engagement
Our goal is to become the leading manufacturer and distributor of sterile IV solutions in East Africa, recognized for quality excellence and innovation, while enhancing health solutions and wellness services that improve patient outcomes across the region.
Partnership
Partnership Proposal Opportunity
International Pharmaceutical Partnership Opportunity
Strategic Manufacturing Alliance in East Africa
Bryant, Mitchell & Omondi (BMO)
Nairobi, Kenya
Executive Summary
Bryant, Mitchell & Omondi (BMO) invites established pharmaceutical companies from South Korea, India, Japan, and other international markets to explore strategic partnership opportunities in the rapidly growing East African healthcare sector.
BMO is a Nairobi-based manufacturer of sterile IV solutions serving hospitals and healthcare facilities across Kenya and East Africa. We offer international pharmaceutical companies a unique opportunity to establish a manufacturing footprint in this high-growth region through various partnership models including joint ventures, contract manufacturing, technology transfer, and distribution agreements.
Market Opportunity: The East African IV solutions market is projected to reach USD 440.57 million by 2030, with a compound annual growth rate (CAGR) of 8.34%. Local manufacturing capacity remains limited, creating significant opportunities for partnership and expansion.
Why Partner with BMO?
Established Manufacturing Infrastructure
✓ Operational Facility in Nairobi
State-of-the-art manufacturing facility with advanced sterilization technology currently producing Normal Saline and Dextrose IV solutions
✓ Regulatory Compliance
Full Kenya Pharmacy and Poisons Board approval, WHO GMP certification, and ISO quality management systems in place
✓ Production Capacity
Current capacity with scalability for expansion, 99.5% filling accuracy with time-pressure control systems
✓ Quality Laboratory
In-house testing capabilities for sterility, endotoxin analysis, chemical composition, and stability studies
Strategic Market Position
✓ Growing Healthcare Market
Kenya's hospital market projected to reach KSh 349 billion ($2.7 billion) by 2029, CAGR of 6.45%
✓ Regional Hub Location
Nairobi serves as commercial and logistics hub for East African Community (EAC) member states
✓ Established Distribution Networks
Existing relationships with major hospitals, clinics, and healthcare procurement agencies
✓ Import Substitution Opportunity
Significant market share currently held by imported products, creating opportunity for competitive local manufacturing
Experienced Management Team
✓ Healthcare Administration Expertise
Co-founder with MHA degree and extensive healthcare policy and hospital management experience
✓ Clinical Leadership
Co-founder physician (MD) with deep understanding of East African clinical needs
✓ Operational Excellence
Track record managing multi-million dollar healthcare budgets and large teams
Favorable Business Environment
✓ Government Support
Kenyan government prioritizes local pharmaceutical manufacturing to reduce import dependency
✓ EAC Integration
Access to expanded East African Community market with harmonized regulatory standards
✓ Competitive Cost Structure
Lower labor and operational costs compared to developed markets
✓ Political Stability
Kenya's established democratic institutions and business-friendly environment
Automated machine filling glass vials with liquid in a pharmaceutical setting.
Partnership Models
Model 1: Joint Venture Manufacturing
Structure:
Equity partnership establishing joint ownership of expanded manufacturing facility
Partner Contributions:
- International Partner: Technology transfer, formulation expertise, quality systems, capital investment, international market access
- BMO: Existing facility and infrastructure, local market knowledge, regulatory relationships, distribution networks, operational management
Benefits for International Partner:
- Shared investment and risk
- Established local presence
- Access to East African market
- Potential for regional expansion
- Local partner managing regulatory compliance
Revenue Model:
Profit sharing based on equity stake, production for both local and export markets
Model 2: Contract Manufacturing
Structure:
BMO manufactures pharmaceutical products under international partner's specifications and brand
Partner Contributions:
- International Partner: Product formulations, quality specifications, raw materials (optional), technical training, brand licensing
- BMO: Manufacturing capacity, quality assurance, regulatory compliance, local distribution
Benefits for International Partner:
- No capital investment required
- Immediate production capacity
- Local regulatory compliance handled by BMO
- Flexible volume commitments
- Established quality systems
Revenue Model:
Per-unit manufacturing fees, volume-based pricing tiers
Model 3: Technology Transfer & Licensing
Structure:
International partner licenses pharmaceutical formulations and manufacturing technology to BMO
Partner Contributions:
- International Partner: Proprietary formulations, manufacturing processes, technical training, quality standards, ongoing technical support
- BMO: Manufacturing facility, market development, regulatory approval, sales and distribution
Benefits for International Partner:
- Royalty revenue stream
- Market expansion without capital investment
- Technology deployment in growing market
- Minimal operational involvement
Revenue Model:
Upfront licensing fees, ongoing royalties based on sales volume
Model 4: Distribution Partnership
Structure:
BMO serves as exclusive distributor for international partner's pharmaceutical products in East Africa
Partner Contributions:
- International Partner: Finished pharmaceutical products, marketing materials, technical support, pricing structure
- BMO: Distribution infrastructure, healthcare relationships, regulatory import compliance, sales and marketing
Benefits for International Partner:
- Access to East African market without local manufacturing
- Established distribution channels
- Local regulatory and cultural expertise
- Healthcare provider relationships
Revenue Model:
Distribution margins, volume commitments, exclusive territory agreements.
The Opportunity
Investment Highlights
Financial Projections (Based on Current Operations)
Year 1-2: Revenue: $16-23M | Net Income: $11-17M
Year 3: Revenue: $28M | Net Income: $19M
Year 5: Revenue: $42M | Net Income: $28M
These projections are based on the current product line's market penetration and relevant Kenyan legislation. By expanding partnerships, particularly in the health solutions and wellness services sectors, we could significantly increase our revenue potential.
Market Size & Growth
Total Addressable Market (TAM): USD 226.21M (2021) → USD 440.57M (2030) | CAGR: 8.34%
Serviceable Available Market (SAM) - Kenya: USD 108.12M (2021) → USD 226.21M (2030) | CAGR: 8.63%
Key Growth Drivers for health solutions and wellness services:
- Increasing healthcare infrastructure investment
- Rising prevalence of chronic diseases
- Growing population (55+ million in Kenya)
- Government healthcare reforms
- Reduced import dependency initiatives
Competitive Advantage
✓ First-Mover Local Manufacturing
Limited local sterile IV production creates a competitive advantage for providing essential health solutions.
✓ Cost Leadership
Local production eliminates import duties, shipping costs, and currency risks, making wellness services more affordable.
✓ Supply Chain Reliability
Reduced dependency on international logistics enhances supply chain reliability and minimizes disruptions to health solutions.
✓ Customization Capability
Ability to develop formulations specific to regional health needs ensures tailored wellness services.
✓ Regulatory Relationships
Established compliance with Kenya Pharmacy and Poisons Board and EAC standards supports the delivery of effective health solutions.
Partnership Requirements
We seek international pharmaceutical partners who can provide health solutions and wellness services with: ✓ Proven track record in pharmaceutical manufacturing ✓ WHO GMP or equivalent certifications ✓ Technology or product portfolio suitable for the East African market ✓ Commitment to quality and patient safety ✓ Interest in long-term market development ✓ Financial capacity for partnership investment (model dependent)